Clinical Trial Update: Treatment of Indolent Systemic Mastocytosis With PA101 [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating PA101 for indolent systemic mastocytosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Indolent Systemic Mastocytosis
• Mastocytosis
• Systemic Mastocytosis

Drugs mentioned

• PA101

Snippet

Sponsor: Patara Pharma | Conditions: Mastocytosis, Systemic Mastocytosis | Phase 2 | Status: COMPLETED